A prospective investigation of the association between GALAD score and the features and survival of hepatocellular carcinoma.

A prospective investigation of the asssociation between GALAD score and the features oand survival of hepatocellular carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20230312003

Enrollment

115

Registered

2023-03-12

Start date

2021-09-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To identify correlation between the GALAD score and tumor feature, HCC staging and patient survival. Hepatocellular carcinoma , GALAD , tumor feature , Survival, HCC staging

Interventions

Patient who have HCC less than 2 cm, patient feel well(PS 0) and liver is woking normally(CTP A or B).,Patient who have single HCC of any size or up to 3 tumors all less than 3 cm. Patient feel well(

Other,Other,Other,Other,Other

Stage 0,Stage A,Stage B,Stage C,Stage D

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Participants must be at least 18 years with first diagnosed HCC base on Barcelona Clinical Liver Cancer (BCLC)

Exclusion criteria

Exclusion criteria: Other primary liver malignancy or liver metastasis

Design outcomes

Primary

Measure	Time frame
relationship between GALAD and HCC feature and survival 6 months tumor characteristic, survival	—

Secondary

Measure	Time frame
relationship between tumor marker and HCC characteristic and staging of HCC at the beginning of study characteristic of HCC, staging of HCC	—

Countries

Thailand

Contacts

Public ContactOraphan Jitpraphawan

Faculty of medicine , Navamintharadhiraj university

oraphan.j@nmu.ac.th0972546642

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026